Temporal regulation of pulmonary inflammation by MyD88 alternative pre-mRNA splicing

MyD88 选择性前 mRNA 剪接对肺部炎症的时间调节

基本信息

  • 批准号:
    10413131
  • 负责人:
  • 金额:
    $ 56.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-06-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Acute inflammatory diseases of the lungs affect more than 100 million people in the U.S. annually. The acute inflammatory response in these patients is required to combat infection but also causes significant tissue damage. Thus, proper resolution of inflammation is critical for patient recovery. Lung airspace macrophages (AMs) serve as key orchestrators of the inflammatory response, functioning in both the initiation and resolution of inflammation. However, the mechanisms used by AMs to direct the resolution of inflammation are incompletely understood. Moreover, two different AM subsets modulate inflammation. Resident AMs are present in the airspaces throughout life; they serve as first responders to pathogens but their inflammatory programs are quickly down-regulated. Recruited AMs arise from circulating monocytes that migrate to the lung during inflammation; inflammatory mediator production by these cells is more persistent than that of resident AMs. The mechanisms that drive the divergent effects of these AM populations on inflammation remain to be elucidates. We have found that alternative pre-mRNA splicing of MyD88, a signaling adaptor that functions in multiple Toll-like receptor and IL-1 receptor signaling pathways, plays a key role in terminating pro- inflammatory mediator production in AMs. Thus we hypothesize that altered splicing of MyD88 provides a central brake on AM pro-inflammatory responses and serves to limit persistent inflammation. We further postulate that the role of MyD88 alternative splicing differs in different AM subpopulations. To test this hypothesis, we will investigate the physiological effect of alternative MyD88 splicing in: (1) mouse resident AMs ex vivo and in vivo, (2) mouse recruited AMs ex vivo and in vivo, and (3) human AMs isolated from patients with acute inflammatory lung disease. These studies will demonstrate the potential utility of targeting this regulatory mechanism to treat patients with acute inflammatory lung disease.
摘要 在美国,急性肺部炎症疾病每年影响超过1亿人。急性 这些患者需要炎症反应来对抗感染,但也会导致严重的组织感染 损害因此,适当解决炎症对患者康复至关重要。肺泡巨噬细胞 (AMs)作为炎症反应的关键协调者,在启动和消退中发挥作用 炎症。然而,AM用于指导炎症消退的机制是 不完全理解。此外,两种不同的AM亚群调节炎症。居民AM是 存在于整个生命的空气空间;他们作为第一反应的病原体,但其炎症 程序被迅速下调。募集的AM来自迁移到肺的循环单核细胞 在炎症过程中,这些细胞产生的炎症介质比常驻细胞产生的炎症介质更持久。 AM驱动这些AM群体对炎症的不同作用的机制仍有待进一步研究。 阐明。我们已经发现MyD 88的前体mRNA的选择性剪接,MyD 88是一种在细胞内起作用的信号衔接子, 多种Toll样受体和IL-1受体信号通路,在终止pro-IL-1的过程中起着关键作用。 AM中的炎性介质产生。因此,我们假设MyD 88的剪接改变提供了一个新的机制。 中枢制动AM促炎反应并用于限制持续性炎症。我们进一步 假设MyD 88选择性剪接的作用在不同的AM亚群中不同。为了验证这一 假设,我们将研究MyD 88选择性剪接的生理效应:(1)小鼠常驻AM 离体和体内,(2)小鼠离体和体内募集的AM,和(3)从患者分离的人AM 急性炎症性肺病这些研究将证明针对这一点的潜在效用。 调节机制,以治疗急性炎症性肺病患者。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis and Characterization of Click Nucleic Acid Conjugated Polymeric Microparticles for DNA Delivery Applications.
  • DOI:
    10.1021/acs.biomac.0c01563
  • 发表时间:
    2021-03-08
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Anderson AJ;Grey E;Bongiardina NJ;Bowman CN;Bryant SJ
  • 通讯作者:
    Bryant SJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott Alper其他文献

Scott Alper的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott Alper', 18)}}的其他基金

MDS-Associated Spliceosome Mutations Regulate Host Defense
MDS 相关剪接体突变调节宿主防御
  • 批准号:
    10097711
  • 财政年份:
    2021
  • 资助金额:
    $ 56.37万
  • 项目类别:
MDS-Associated Spliceosome Mutations Regulate Host Defense
MDS 相关剪接体突变调节宿主防御
  • 批准号:
    10370289
  • 财政年份:
    2021
  • 资助金额:
    $ 56.37万
  • 项目类别:
MDS-Associated Spliceosome Mutations Regulate Host Defense
MDS 相关剪接体突变调节宿主防御
  • 批准号:
    10559529
  • 财政年份:
    2021
  • 资助金额:
    $ 56.37万
  • 项目类别:
Temporal regulation of pulmonary inflammation by MyD88 alternative pre-mRNA splicing
MyD88 选择性前 mRNA 剪接对肺部炎症的时间调节
  • 批准号:
    10175016
  • 财政年份:
    2019
  • 资助金额:
    $ 56.37万
  • 项目类别:
Molecular mechanisms utilized by novel innate immunity regulators
新型先天免疫调节剂利用的分子机制
  • 批准号:
    7977056
  • 财政年份:
    2010
  • 资助金额:
    $ 56.37万
  • 项目类别:
Molecular mechanisms utilized by novel innate immunity regulators
新型先天免疫调节剂利用的分子机制
  • 批准号:
    8145234
  • 财政年份:
    2010
  • 资助金额:
    $ 56.37万
  • 项目类别:

相似海外基金

Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.37万
  • 项目类别:
    Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
  • 批准号:
    10722669
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
  • 批准号:
    491387
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
    Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
  • 批准号:
    10678788
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
  • 批准号:
    10646578
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
  • 批准号:
    23K08447
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
  • 批准号:
    10601865
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
  • 批准号:
    23K08360
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
  • 批准号:
    10722194
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
  • 批准号:
    10594793
  • 财政年份:
    2023
  • 资助金额:
    $ 56.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了